BeStock  
Stocks › Biotechnology › RXRX

Recursion Pharmaceuticals RXRX

US equityMarket cap rank #2863BiotechnologyAI medical concept stocks
$2.45 −$0.27 (-9.93%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $2.51 +2.39%
Open$2.63
Prev close$2.72
Day range$2.44 – $2.76
Volume29.88M
Market cap$1.53B
P/E (TTM)–
Dividend yield–

RXRX Stock News

Headlines matching Recursion Pharmaceuticals or the RXRX ticker, most recent first.

  • BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold RatingMarket news · 21 Sep 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)TipRanks · 21 Sep 2026 · Direct mention
  • Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (RXRX), Teladoc (TDOC) and Oscar Health (OSCR)TipRanks · 16 Sep 2026 · Direct mention
  • J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy RatingMarket news · 16 Sep 2026 · Direct mention
  • Recursion Pharmaceuticals (RXRX) Gets a Hold From Bank of America SecuritiesTipRanks · 7 Aug 2026 · Direct mention
  • TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold RatingMarket news · 6 Aug 2026 · Direct mention
  • Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $8Market news · 6 Aug 2026 · Direct mention
  • Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3 NegativeMarket news · 17 Aug 2026 · Direct mention
  • BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $6Market news · 12 Aug 2026 · Direct mention
  • Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.5 PositiveMarket news · 14 May 2026 · Direct mention
  • J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10 NegativeMarket news · 30 Apr 2026 · Direct mention
  • BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $6 NegativeMarket news · 26 Feb 2026 · Direct mention
  • Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson BlakeSEC · 5 Nov 2026 · Related
  • News Flash: Analysts Just Made A Meaningful Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts PositiveSimply Wall St · 5 Nov 2026 · Direct mention
  • Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hassan FredSEC · 5 Nov 2026 · Related

Discussion

No comments yet — be the first to weigh in on RXRX.

Sign in to join the discussion.

Scroll to Top